News
INNMF
0.100
NaN%
--
Amplia lodges updated ASX corporate governance statement for 2026
TipRanks · 05/29 05:57
Amplia Therapeutics details ASX-aligned corporate governance framework
TipRanks · 05/29 03:58
Amplia Highlights Cancer and Fibrosis Focus in 2025-26 Report
TipRanks · 05/29 03:48
Amplia launches Phase 2b pancreatic cancer trial of narmafotinib with daily dosing
PUBT · 05/19 12:45
Amplia Therapeutics launches Phase 2b narmafotinib trial in advanced pancreatic cancer
PUBT · 05/18 22:58
Amplia Therapeutics issues 240,385 shares on CMO option exercise under equity plan
PUBT · 05/12 06:53
Amplia Issues New Shares Under Executive Equity Plan, Affirms Regulatory Compliance
TipRanks · 05/12 06:04
Amplia Therapeutics Adds 240,385 New Shares to ASX Listing
TipRanks · 05/12 05:51
Amplia, ANZGOG launch PRROSE ovarian cancer trial of narmafotinib plus chemotherapy
PUBT · 05/10 00:01
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
Barchart · 05/08 19:45
Amplia, ANZGOG launch PRROSE ovarian cancer trial of narmafotinib with chemotherapy
PUBT · 05/08 16:49
Amplia and ANZGOG launch narmafotinib ovarian cancer trial targeting high‑need patients
TipRanks · 05/08 00:59
Amplia advances narmafotinib program with strong pancreatic cancer data and Phase 3 readiness steps
TipRanks · 04/28 00:11
Amplia presents mature ACCENT pancreatic cancer trial data at AACR meeting
PUBT · 04/22 12:45
Accent Trial Mature Data Presented at International Conference
Barchart · 04/22 07:45
Amplia MD says AMPLICITY halt driven by mFOLFIRINOX DLTs, not narmafotinib
Reuters · 04/08 04:46
Amplia Halts New Recruitment in Pancreatic Cancer Trial After Chemo Toxicities
TipRanks · 04/08 04:12
Amplia halts AMPLICITY pancreatic cancer trial recruitment after three chemotherapy-related DLTs
Reuters · 04/07 06:56
Amplia Halts AMPLICITY Recruitment, Shifts Focus to Less Toxic Pancreatic Cancer Regimens
TipRanks · 04/06 23:33
More
Webull provides a variety of real-time INNMF stock news. You can receive the latest news about Amplia Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About INNMF
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.